201.21
-1.82 (-0.90%)
| Previous Close | 203.03 |
| Open | 199.08 |
| Volume | 156,409 |
| Avg. Volume (3M) | 322,640 |
| Market Cap | 5,823,617,024 |
| Price / Earnings (TTM) | 30.21 |
| Price / Earnings (Forward) | 29.24 |
| Price / Sales | 17.36 |
| Price / Book | 5.53 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.18 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Krystal Biotech, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.88% |
| % Held by Institutions | 104.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 255.00 (B of A Securities, 26.73%) | Buy |
| Median | 230.00 (14.31%) | |
| Low | 198.00 (Citigroup, -1.60%) | Hold |
| Average | 228.25 (13.44%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 188.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 04 Nov 2025 | 220.00 (9.34%) | Buy | 203.26 |
| Citigroup | 04 Nov 2025 | 198.00 (-1.60%) | Hold | 203.26 |
| B of A Securities | 17 Oct 2025 | 255.00 (26.73%) | Buy | 190.23 |
| HC Wainwright & Co. | 15 Sep 2025 | 240.00 (19.28%) | Buy | 155.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Nov 2025 | Announcement | Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference |
| 03 Nov 2025 | Announcement | Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results |
| 21 Oct 2025 | Announcement | Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 |
| 14 Oct 2025 | Announcement | Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis |
| 15 Sep 2025 | Announcement | Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label |
| 02 Sep 2025 | Announcement | Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |